| |
| |
|
| Insider
Information: |
Goldstein Dov A Md |
| Relationship: |
Director |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
113,515 |
|
|
Indirect Shares
|
9,937,297 |
|
|
| Direct
Value |
$213,256 |
|
|
|
Indirect Value
|
$18,973,360 |
|
|
| Total
Shares |
10,050,812 |
|
|
| Total
Value |
$19,186,617 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Melinta Therapeutics, Inc |
MLNT |
Director |
2017-03-08 |
95 |
2017-03-08 |
0 |
Premium* |
|
|
ADMA Biologics Inc |
ADMA |
Director |
2020-02-28 |
7,500 |
2012-02-13 |
2,516,855 |
Premium* |
|
|
Durata Therapeutics, Inc. |
DRTX |
Director, 10% Owner |
2012-07-24 |
0 |
2012-07-24 |
3,130,824 |
Premium* |
|
|
Esperion Therapeutics, Inc. |
ESPR |
Director |
2018-06-06 |
47 |
2017-03-22 |
837,125 |
Premium* |
|
|
Loxo Oncology, Inc. |
LOXO |
CFO and Treasurer, 10%... |
2015-04-02 |
65,873 |
2015-04-02 |
3,452,493 |
Premium* |
|
|
Neubase Therapeutics Ord Shs |
NBSE |
Director |
2021-06-18 |
30,000 |
2020-04-30 |
0 |
Premium* |
|
|
Coya Therapeutics, Inc. |
COYA |
Director |
2023-01-03 |
10,000 |
2023-01-03 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
39 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| MLNT |
Melinta Therapeutics, Inc |
Director |
– • – |
2017-03-08 |
4 |
S |
$3.57 |
$356,443 |
I/I |
(99,900) |
0 |
0 |
- |
|
| ESPR |
Esperion Therapeutics, In... |
Director |
– • – |
2017-12-05 |
4 |
A |
$0.00 |
$0 |
D/D |
38 |
47 |
0 |
- |
|
| ESPR |
Esperion Therapeutics, In... |
Director |
– • – |
2017-12-18 |
4 |
D |
$0.00 |
$0 |
D/D |
(21,471) |
47 |
0 |
- |
|
| ESPR |
Esperion Therapeutics, In... |
Director |
– • – |
2018-06-06 |
4 |
D |
$0.00 |
$0 |
D/D |
(13,000) |
47 |
0 |
- |
|
| MLNT |
Melinta Therapeutics, Inc |
Director |
– • – |
2015-06-22 |
4 |
AS |
$35.74 |
$1,787,000 |
D/D |
(50,000) |
50 |
0 |
- |
|
| MLNT |
Melinta Therapeutics, Inc |
Director |
– • – |
2016-01-04 |
4 |
AS |
$30.06 |
$25,314 |
D/D |
(842) |
50 |
0 |
- |
|
| MLNT |
Melinta Therapeutics, Inc |
Director |
– • – |
2016-01-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
842 |
892 |
0 |
- |
|
| ADMA |
ADMA Biologics Inc |
Director |
– • – |
2020-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
7,500 |
0 |
- |
|
| NBSE |
Neubase Therapeutics Ord ... |
Director |
– • – |
2020-04-30 |
4 |
B |
$6.00 |
$60,000 |
D/D |
10,000 |
10,000 |
2.39 |
- |
|
| COYA |
Coya Therapeutics, Inc. |
Director |
– • – |
2023-01-03 |
4 |
B |
$0.00 |
$0 |
D/D |
10,000 |
10,000 |
2.31 |
- |
|
| ESPR |
Esperion Therapeutics, In... |
Director |
– • – |
2018-06-06 |
4 |
OE |
$14.42 |
$214,100 |
D/D |
13,000 |
13,047 |
0 |
- |
|
| ESPR |
Esperion Therapeutics, In... |
Director |
– • – |
2017-12-18 |
4 |
OE |
$3.70 |
$79,443 |
D/D |
21,471 |
21,518 |
0 |
- |
|
| NBSE |
Neubase Therapeutics Ord ... |
Director |
– • – |
2021-04-26 |
4 |
B |
$5.00 |
$60,000 |
D/D |
12,000 |
22,000 |
2.39 |
- |
|
| LOXO |
Loxo Oncology, Inc. |
CFO and TreasurerOfficer |
• • • |
2014-07-31 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
22,656 |
|
- |
|
| NBSE |
Neubase Therapeutics Ord ... |
Director |
– • – |
2021-06-18 |
4 |
B |
$4.75 |
$38,000 |
D/D |
8,000 |
30,000 |
2.39 |
- |
|
| MLNT |
Melinta Therapeutics, Inc |
Director |
– • – |
2015-06-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
50,000 |
50,050 |
0 |
- |
|
| LOXO |
Loxo Oncology, Inc. |
CFO and Treasurer |
• – • |
2015-04-01 |
4 |
OE |
$3.65 |
$253,249 |
D/D |
39,212 |
61,868 |
0 |
- |
|
| LOXO |
Loxo Oncology, Inc. |
CFO and Treasurer |
• – • |
2015-04-02 |
4 |
OE |
$3.65 |
$25,629 |
D/D |
4,005 |
65,873 |
0 |
- |
|
| MLNT |
Melinta Therapeutics, Inc |
Director |
– • – |
2017-03-07 |
4 |
S |
$3.53 |
$176,673 |
I/I |
(50,100) |
99,900 |
0 |
- |
|
| MLNT |
Melinta Therapeutics, Inc |
Director |
– • – |
2017-01-13 |
4 |
S |
$3.40 |
$358,564 |
I/I |
(105,460) |
150,000 |
0 |
- |
|
| LOXO |
Loxo Oncology, Inc. |
CFO and TreasurerOfficer |
• • • |
2014-07-31 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
188,707 |
|
- |
|
| MLNT |
Melinta Therapeutics, Inc |
Director |
– • – |
2017-01-06 |
4 |
S |
$3.64 |
$1,592,864 |
I/I |
(437,600) |
255,460 |
0 |
- |
|
| MLNT |
Melinta Therapeutics, Inc |
Director |
– • – |
2017-01-05 |
4 |
S |
$3.20 |
$1,600,000 |
I/I |
(500,000) |
693,060 |
0 |
- |
|
| ESPR |
Esperion Therapeutics, In... |
Director |
– • – |
2017-03-22 |
4 |
S |
$38.82 |
$12,136,762 |
I/I |
(312,642) |
837,125 |
0 |
- |
|
| ESPR |
Esperion Therapeutics, In... |
Director |
– • – |
2017-03-21 |
4 |
S |
$43.48 |
$21,190,326 |
I/I |
(487,358) |
1,149,767 |
0 |
- |
|
39 Records found
|
|
Page 1 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
